Does Cigna Cover Rezdiffra (Resmetirom)?

Cigna's Coverage Policy for Rezdiffra

Cigna commercial PPO and HMO plans classify Rezdiffra (resmetirom) as a covered specialty medication for the treatment of MASH with moderate to advanced hepatic fibrosis. This coverage became effective after the FDA granted accelerated approval to resmetirom in March 2024, making it the first drug approved specifically for noncirrhotic MASH with liver fibrosis staged at F2 or F3.

Coverage is not automatic. Cigna requires prior authorization (PA) for every Rezdiffra prescription, and some plan documents also reference precertification for compounded formulations. Your prescriber's office will need to submit clinical documentation before the pharmacy can dispense the medication.

Cigna employer-sponsored plans may have different formulary rules than Cigna's standard commercial book of business. Self-funded employer plans set their own pharmacy benefit terms, which means a colleague at a different company with Cigna insurance might face different PA criteria or a different cost-sharing structure than you do. Always verify your specific plan's drug formulary through the myCigna portal or by calling the member services number on your insurance card.

Cigna Medicare Advantage and Cigna Medicaid managed care plans follow separate formulary processes. The information in this article applies primarily to Cigna commercial (employer-sponsored and individual marketplace) plans [1].

Prior Authorization Criteria: What Cigna Requires

The PA process for Rezdiffra on Cigna is rated as moderate difficulty, meaning most requests are approved when the prescriber submits complete documentation, but incomplete submissions are a common cause of initial denial.

Cigna's PA criteria generally require the following clinical documentation:

• A confirmed diagnosis of MASH (previously called NASH or nonalcoholic steatohepatitis)
• Evidence of moderate to advanced hepatic fibrosis, typically staged as F2 or F3 via liver biopsy, FibroScan (vibration-controlled transient elastography), or validated noninvasive biomarker panels such as the FIB-4 index or Enhanced Liver Fibrosis (ELF) test
• Prescribing by, or in consultation with, a hepatologist or gastroenterologist
• Documentation that the patient does not have decompensated cirrhosis (Child-Pugh class B or C)

The MAESTRO-NASH trial (N=966), published in the New England Journal of Medicine in 2024, enrolled adults with biopsy-confirmed NASH and fibrosis stages F1B through F3. At 52 weeks, 25.9% of patients receiving resmetirom 80 mg and 29.9% of patients receiving resmetirom 100 mg achieved NASH resolution without worsening of fibrosis, compared with 9.7% on placebo [2]. These efficacy data form the clinical basis for payer coverage decisions, including Cigna's.

Turnaround time for a standard Cigna PA decision is typically 5 to 15 business days for non-urgent requests. Urgent or expedited requests can be processed within 24 to 72 hours if the prescriber documents clinical urgency [3].

Formulary Tier and Cost-Sharing

Rezdiffra sits on the specialty tier (Tier 4 or Tier 5) of most Cigna commercial formularies. Specialty-tier placement means higher out-of-pocket costs compared with preferred brand or generic medications.

Typical cost-sharing for specialty-tier drugs on Cigna commercial plans falls into one of these structures:

• A flat specialty copay ranging from $100 to $500 per fill
• A coinsurance percentage (commonly 25% to 33%) applied to the drug's negotiated cost
• A combination of coinsurance with a per-prescription maximum

At the list price of approximately $3,500 per month, a 30% coinsurance rate would produce a $1,050 monthly out-of-pocket cost before any copay assistance or accumulator adjustments. Many Cigna plans also apply specialty drug spending toward the annual out-of-pocket maximum, which can reduce costs later in the plan year.

One variable that catches patients off guard: Cigna copay accumulator and maximizer programs. Some Cigna plans use copay accumulator adjustment programs that prevent manufacturer copay card payments from counting toward your deductible or out-of-pocket maximum. If your plan has this feature, you may exhaust manufacturer copay assistance and then face the full coinsurance obligation mid-year. Ask your Cigna plan administrator whether a copay accumulator applies to specialty medications on your specific plan [4].

Step Therapy: Does Cigna Require Other Treatments First?

Some Cigna plan designs include step therapy (also called "fail-first") protocols before approving Rezdiffra. Because resmetirom is the only FDA-approved pharmacotherapy for MASH with fibrosis, step therapy for Rezdiffra does not typically require failure on another MASH-specific drug. Instead, step therapy criteria on certain Cigna plans may require documentation that the patient has attempted lifestyle interventions (structured diet modification, exercise programs, and weight management) prior to pharmacotherapy approval.

This is a meaningful distinction. Cigna is not asking patients to fail on an alternative MASH drug. The step therapy requirement, where it exists, centers on lifestyle modification documentation.

Your prescriber can request a step therapy exception if lifestyle interventions are medically inappropriate or if the patient's fibrosis progression makes delaying pharmacotherapy clinically risky. The American Association for the Study of Liver Diseases (AASLD) practice guidance recommends pharmacotherapy for patients with biopsy-confirmed NASH and significant fibrosis (F2 or greater), which supports exception requests for patients meeting these criteria [5].

How to Appeal a Cigna Denial for Rezdiffra

If Cigna denies your Rezdiffra PA request, you have access to a structured two-level internal appeal process followed by an external independent review organization (IRO) review.

First-level internal appeal. You or your prescriber must file a written appeal within 180 days of the denial notice. Include the original denial letter, updated clinical documentation, and a letter of medical necessity from the prescribing physician. Reference the MAESTRO-NASH trial data showing statistically significant NASH resolution and fibrosis improvement with resmetirom versus placebo [2]. Cigna must respond to standard first-level appeals within 30 calendar days.

Second-level internal appeal. If the first appeal is denied, submit a second-level appeal with additional supporting documentation. Consider including peer-reviewed literature, specialist consultation notes, and any progression in liver disease since the initial request. Cigna reviews second-level appeals with a different medical reviewer than the one who made the first-level decision.

External independent review. After exhausting both internal appeal levels, you can request an external review by an independent review organization. The external reviewer is not affiliated with Cigna and evaluates whether the denial was medically appropriate. Under the Affordable Care Act and most state insurance regulations, the external IRO decision is binding on Cigna [6].

Dr. Zobair Younossi, Chairman of the Department of Medicine at Inova Fairfax Medical Campus and a leading MASH researcher, has stated: "For patients with significant fibrosis, delaying effective treatment increases the risk of progression to cirrhosis, liver failure, and hepatocellular carcinoma. Timely access to approved therapies is a clinical priority" [7].

A practical tip: the most common reason for Rezdiffra PA denials on Cigna is incomplete documentation of fibrosis staging, not medical disagreement about the drug's appropriateness. Before filing an appeal, confirm that your prescriber has submitted the FibroScan report, liver biopsy pathology, or validated noninvasive fibrosis score. A complete resubmission often resolves the issue faster than a formal appeal.

Using the Manufacturer Savings Card with Cigna

Madrigal Pharmaceuticals, the maker of Rezdiffra, offers a copay savings program for eligible commercially insured patients. The program can reduce out-of-pocket costs to as low as $0 per month for qualifying patients, subject to annual maximum benefit limits.

Eligibility requirements for the manufacturer copay card typically include:

• Coverage under a commercial (non-government) insurance plan
• A valid, approved prescription for Rezdiffra
• Not enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government healthcare program

Patients with Cigna commercial insurance are generally eligible. The savings card works as a secondary payer, covering the difference between your Cigna plan's cost-sharing amount and the program's copay target.

The critical caveat is the copay accumulator issue described above. If your Cigna plan uses a copay accumulator adjustment program, the manufacturer card payments will not count toward your deductible. You should verify this with Cigna before relying on the savings card as your full-year cost management strategy.

Madrigal also operates a patient assistance program (PAP) for uninsured or underinsured patients who meet income eligibility criteria. If you have Cigna insurance but your plan explicitly excludes Rezdiffra, the PAP may be an alternative pathway [8].

Clinical Context: Why Rezdiffra Matters for MASH

Rezdiffra (resmetirom) is a thyroid hormone receptor beta (THR-β) selective agonist. It targets the liver specifically, activating THR-β to reduce hepatic fat, improve lipid metabolism, and decrease markers of liver inflammation and fibrosis without causing the systemic thyroid effects (tachycardia, bone loss, muscle wasting) associated with non-selective thyroid hormone analogs [9].

Before resmetirom's approval, no FDA-approved pharmacotherapy existed for MASH. Treatment was limited to lifestyle modification, management of comorbid conditions (type 2 diabetes, obesity, dyslipidemia), and consideration of off-label agents such as pioglitazone or vitamin E.

In the MAESTRO-NASH phase 3 trial, resmetirom 100 mg daily produced a statistically significant improvement in the two co-primary endpoints at week 52: NASH resolution without worsening fibrosis (29.9% vs. 9.7% placebo, P<0.001) and at least one-stage improvement in fibrosis without worsening of NAFLD Activity Score (25.9% vs. 14.2% placebo, P<0.001) [2]. These results led the FDA to grant accelerated approval on March 14, 2024.

MASH affects an estimated 6.1 million adults in the United States, according to epidemiologic modeling data published in Hepatology [10]. Among those with F2-F3 fibrosis, the risk of progression to cirrhosis within 5 to 10 years ranges from 20% to 40%, depending on metabolic comorbidities and disease activity [11]. This progression risk underlies the clinical argument for timely insurance coverage and pharmacotherapy access.

Cigna vs. Other Major Insurers: Coverage Comparison

Cigna's coverage posture for Rezdiffra is broadly comparable to other large commercial payers. UnitedHealthcare, Aetna, and Blue Cross Blue Shield plans have similarly placed Rezdiffra on specialty tiers with PA requirements. The PA criteria across payers converge on the same core elements: confirmed MASH diagnosis, fibrosis staging (F2-F3), and prescriber specialty documentation.

Where Cigna differs in some plan designs is the potential step therapy requirement for documented lifestyle interventions. Not all payers enforce this. UnitedHealthcare's standard commercial PA criteria, for example, focus on diagnosis and fibrosis staging without an explicit lifestyle modification step [12].

Cigna's two-level internal appeal process is standard under ACA regulations. The external IRO review is also a federal requirement. The practical difference between insurers often comes down to PA turnaround time and the specificity of documentation requests, not the existence of the appeal pathway itself.

Monitoring and Follow-Up Requirements

Cigna's PA approval for Rezdiffra is typically time-limited, often 6 to 12 months, after which a renewal PA is required. For the renewal, your prescriber will need to document:

• Ongoing adherence to resmetirom therapy
• Clinical response, which may include improvement or stability in fibrosis markers (FibroScan, FIB-4) or liver enzymes (ALT, AST)
• Absence of contraindications or significant adverse effects

Common laboratory monitoring during resmetirom therapy includes liver function tests (ALT, AST, bilirubin), thyroid function (TSH, free T4), and lipid panels. In the MAESTRO-NASH trial, resmetirom produced significant reductions in LDL cholesterol (approximately 14% to 22% reduction) and triglycerides, which represents a secondary cardiovascular benefit worth tracking [2].

The FDA label recommends monitoring hepatic function tests before initiating treatment and periodically during therapy. Resmetirom is contraindicated in patients with decompensated cirrhosis (Child-Pugh B or C), and treatment should be discontinued if signs of hepatic decompensation develop [1].

Patients on Cigna plans should keep copies of all lab work and imaging reports. Having this documentation organized before the renewal PA submission date reduces the risk of a coverage lapse.

The recommended dose of resmetirom is 80 mg once daily for patients weighing <100 kg and 100 mg once daily for patients weighing ≥100 kg, taken with food [1].